VIROKLENZ-HELPERBY: OUR STORY
Helperby ARB technology outsmarts antibiotic resistance. Antibiotic Resistance is the biggest threat to modern medicine. It already costs over 700,000 lives per annum globally (pre COVID).
The Viroklenz tech team, George Bridge and Paul Pelham were first introduced to Professor Coates in 2015. This was the first of many development meetings, these continue to the present day.
Objective 1To produce the best alcohol-free sanitisers and disinfectant /cleaners. Skin safe and effective against anti-microbial resistant bacteria. Obtain a world wide patent. In 2018 The emoulluene was successfully blended into the CHX Chlorhexidine FORMULA. In 2019 A pre-mix process was developed by Viroklenz to enable scaled up volume. This replaced all the post mix formulations. In 2020 The new CHX HT-61 blend was tested for efficacy against COVID -19 and hand sanitisation to British Standards EN1500 and EN1447. In 2021 The world wide patent was granted. This highlighted the need for the formation of Viroklenz-Helperby Licensing. |
Objective 2Commercialisation of the product available worldwide. A: To produce HT-61 CHX on a commercial scale. B: To work with a UK based fine chemical blender, Thomas Swan & Co who are capable of undertaking this commercial scale work. C: The technical process and procedure are provided by Viroklenz and are patent pending. D: Once the HT-61 production process is established and is packaged as a concentrate ingredient, it would be supplied to Brenntag world wide with the other ingredients to make emoulluene. E: Halal approval - Received July 2021. F: Large scale availability in 2022. G: Distribution by DeeSet Logistics - Turbo Statics. |
